Back to Studies

P1114 / Safety and Immunogenicity of an RSV Vaccine cps2

A Phase I Study of the Safety and Immunogenicity of a Single Dose of the Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine RSV cps2,
Lot RSV#005A, Delivered as Nose Drops to RSV-Seronegative
Infants and Children 6 to 24 Months of Age

Loading study documents...
Loading study sites...
Loading study protocol team...
Loading study press...
Loading study publications/presentations...